Joseph Munyi, a Kenyan citizen, has been living with HIV for 8 years and, much like other HIV patients, is unemployed. He has been receiving his medication free of charge on account of government programmes and outreach programmes of Medicine Sans Frontieres. His medication comes in the form of generic drugs. However, this situation may not last long as economic interests of few may end up impeding many a public spirited...
More »SEARCH RESULT
No shelter, Myanmar refugees asked to move out yet again-Shaswati Das
Twenty-seven-year-old Amina (name changed) is in the eighth month of her pregnancy. But this immigrant from the Rohingya community from Myanmar is more worried about getting a shelter over her head than the bundle of joy she would be holding in her arms very soon. She is among the 2,500-odd Rohingya refugees who were camping at Vasant Vihar before they moved to Sultan Garhi on May 8. They not only lack...
More »Protests in US over high pricing of Novartis' anti-cancer drug Glivec-Divya Rajagopal
Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...
More »The government needs to think out of the box to help pharma grow while keeping medicines affordable-Ramesh Adige
Having watched from the ringside for many years now, I have no doubt in advising that the steering wheel must be firmly grasped by the government and direction given to policies that should be stable for at least the medium term. This is crucial for the growth of Indian pharma, a $20-billion industry growing at an average of 12% considering both domestic and export arenas. Price control: The biggest and most...
More »A healthier India: Need to resolve conflict between drug price controls, innovation and affordable healthcare-David Taylor
The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...
More »